DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

Hims & Hers vs IVIM Health: November 2026 prices compared

As of November 20, 2026, neither Hims & Hers nor IVIM Health printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.

Released · Last reviewed · how we verify

Hims & Hers and IVIM Health, measure by measure

Hims & Hers and IVIM Health side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureHims & HersIVIM Health
Tirzepatide, month to month—from $192 (per month, starting-dose price)
Tirzepatide, lowest printed—$192 ($117 + $75 program fee)
Semaglutide, month to month—from $140 (per month, starting-dose price)
Semaglutide, lowest printed—$140 ($65 + $75 program fee)
Dose pricingnot confirmedpriced by dose or not stated
Membership or program feenot confirmedabout $75 a month
Computed scorenot scored (brand route)8 of 40 (position 18 of 27)
FDA warning letters716567 (2025-09-09); 716825 (2025-09-09)721816 (2026-02-20)
November 20 readnot readable Nov 20first-party read

Strengths and limitations: which fits whom

Hims & Hers suits someone who wants brand medication, FDA-approved, and accepts a higher monthly cost or has coverage. IVIM Health prices by dose, so its printed figure covers the first months; budget for a higher maintenance-dose price. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

What changed since August

The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.

What changed since the August 2026 capture (maintenance-dose all-in figure then; month-to-month all-in figure read November 20, 2026)
ProgramMedicationAugust 5–10, 2026November 20, 2026
IVIM Healthtirzepatide—from $192
IVIM Healthsemaglutide—from $140

Regulatory record

FDA’s warning-letter index lists warning letter 716567 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) and warning letter 716825 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Hims & Hers; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 721816 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to IVIM Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check Hims & Hers’s current prices ↗
Check IVIM Health’s current prices ↗

Frequently asked

Which is cheaper, Hims & Hers or IVIM Health?

Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.

Do Hims & Hers and IVIM Health charge a membership fee?

Hims & Hers: not confirmed on November 20, 2026; IVIM Health: about $75 a month on top of medication. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are Hims & Hers and IVIM Health medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

Hims & Hers recordIVIM Health recordIVIM Health alternativesAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.